Oxstones Investment Club™Pharmaceutical companies have discovered that CIS countries, such as Russia, Ukraine, Belarus and Georgia contain large pools of potential candidates ready to participate in clinical trials. However, certain circumstances have made it necessary for companies to be informed about the conditions in each country in order to proceed through the phases of a trial in an efficient and timely manner. For many companies, time is of the essence as they seek to replace products with patents nearing the expiration date.
As an aid to industry professionals, PMR Publishing has prepared Clinical trials in CIS countries 2012: Russia, Ukraine, Belarus and Georgia, Development forecasts for 2012-2014, a new report that delivers data, comparative analysis and forecasts that enable companies to navigate the obstacles and take advantage of the opportunities offered by each of these countries.
“Nowadays it is more and more difficult to find treatment-naïve patients who would be also willing to participate in clinical studies. CIS countries, due to their large populations as well as less developed healthcare systems, are currently an opportunity for pharmaceutical companies to recruit fast study participants. The markets are also quite difficult due to unclear legislation and specific business climates. Our report will help both those companies wanting to begin studies in the region, as well as those already operating on the market, to plan strategies. For this comparative analysis we have chosen the four countries with the largest number of clinical trials conducted: Russia, Ukraine, Belarus and Georgia.”
In order to locate and capitalize on new opportunities, you need direct access to the latest news, sharpest analysis, most reliable statistics and knowledgeable trends forecasting available. Read Clinical trials in CIS countries 2012: Russia, Ukraine, Belarus and Georgia, Development forecasts for 2012-2014 today, and refer to this new report from PMR on a regular basis as you monitor market expansion and contemplate new business strategies.
The document quantifies the number of clinical trials, market values, locations where trials are being conducted, the companies conducting them, and the therapeutic areas most often investigated. It examines the trends and conditions that have influenced market growth in recent years, and analyses those that have presented obstacles. The report offers profiles of the pharmaceutical corporations actively conducting trials, as well as the most prevalent CROs and sponsors in the region.
In addition to specific data on clinical trial registration time periods, the report lists specific business and legal regulations that might interfere with a trial schedule. It also supplies accurate forecasts for the trials to be completed in these four countries for the period to 2014.
While preparing Clinical trials in CIS countries 2012: Russia, Ukraine, Belarus and Georgia, Development forecasts for 2012-2014 , PMR’s expert analysts have consulted their most reliable sources and created a truly unique market guide that deals with the complexities intrinsic to both the current status and future progression of this dynamic marketplace.
Please visit placelinkhere.com to learn more about the market for clinical trials in the CIS countries of Russia, Ukraine, Belarus and Georgia.
For more information on the report please contact:
Marketing Department:
tel. /48/ 12 618 90 00
e-mail: marketing@pmrcorporate.com
Tags: Belarus, cis nations, clinical trials, drug testing, Georgia, human trials, pharma R&D, R&D outsourcing, research and development, russia, ukraine